Keryx in-licenses phosphate binder

Panion & BF Biotech (Taiwan) granted KERX a worldwide license to Zerenex, an oral, iron-based phosphate binder that is in Phase II trials to treat hyperphosphatemia in patients with end-stage renal disease (ESRD). The deal excludes certain Asian-Pacific countries. Panion will receive an upfront payment and is eligible for milestones and royalties. ...